For research use only. Not for therapeutic Use.
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent[1][2].
Furegrelate Sodium (1-5 mg/kg; po) prevents blockage of the coronary artery[1].
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation[1].
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature[2].
Furegrelate has a long half-life compared to several other drugs used to treat PAH, including nitric oxide and prostagcyclin analogues; And Furegrelate is highly specific to the target enzyme[2].
| Catalog Number | I011811 |
| CAS Number | 85666-17-7 |
| Synonyms | sodium;5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate |
| Molecular Formula | C15H10NNaO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H11NO3.Na/c17-15(18)14-8-12-7-10(3-4-13(12)19-14)6-11-2-1-5-16-9-11;/h1-5,7-9H,6H2,(H,17,18);/q;+1/p-1 |
| InChIKey | XBTIPIZROJAKOJ-UHFFFAOYSA-M |
| SMILES | C1=CC(=CN=C1)CC2=CC3=C(C=C2)OC(=C3)C(=O)[O-].[Na+] |
| Reference | [1]. Gorman RR, et al. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3′-pyridinylmethyl)benzofuran-2-carboxylate. Prostaglandins. 1983 Aug;26(2):325-42. [2]. Hirenallur-S DK, et al. Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets. Pulm Circ. 2012 Apr-Jun;2(2):193-200. |
